ClinicalTrials.gg
RecruitingNCT06151002PD FrontlineUpdated Oct 29, 2026

PD Frontline (Part of RAPSODI GD) Remote Assessment of People With Parkinson's

An observational study in Parkinson Disease, sponsored by University College, London. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by University College, London · Observational

How we know

From the registry’s dates

  • Started Feb 2020; still recruiting 6 years 9 months later.
Updated Oct 29, 2026Primary completion movedEnrollment updated+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
20,000
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Parkinson Disease by University College, London — 4 open to participants now, 4 under way, 2 of them phase 3. Parkinson Disease · University College, London.

Started
2020
with 1 other
Observational
4 of 16
2 open now
Registered
15th of 16
by date

Among the 16 studies in Parkinson Disease by University College, London, this one is one of 2 that started in 2020, is one of 4 observational ones, and was the 15th registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

4 of the 16 studies in Parkinson Disease by University College, London are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Parkinson Disease by University College, London, or all of them as a file.
02

Study summary

PD Frontline (part of RAPSODI GD) is an online study observational study for People with Parkinson's. The aims are to better understand the genetic nature of Parkinson's and to connect participants to clinical trials and studies, particularly those with a genetic focus.

To do this, participants are offered genetic sequencing for two common genetic risk factors for Parkinson's Disease, the GBA1 and LRRK2 gene, with an at-home sample collection kit. Return postage is free.

Read the detailed description

PD Frontline is an online one-time questionnaire based study with the purpose of identifying potential candidates for gene targeted trials and observational studies. The study also seeks to better characterise GBA1 risk factors for Parkinson's Disease.

Once the questionnaire is completed, the participant is sent a sample collection kit in the post for use in genetic testing. The genes tested for are GBA1, the most common risk factor gene for Parkinson's, and LRRK2.

Once tested and where consent is in place, the participant is informed of their results and kept up-to-date with any studies or trials for which they may be eligible. Individuals identified to have genetic variants are contacted by the team to discuss, all participants are sent a report via their study profile.

Participants are kept up-to-date with any study outcomes via newsletters.

03

Conditions studied

  • Parkinson Disease

Browse trials for

Keywords

  • GBA1
  • LRRK2
  • Parkinson's
  • PD
  • Parkinson
  • genetic
04

Who can participate

The criteria were revised on the registry on Oct 29, 2026. See what changed

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Randomly selected population, recruited via established NHS sites and self-referral to the website.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Formal diagnosis of Parkinson Disease

Exclusion criteria

Exclusion Criteria:

  • Confirmation that the individual carries a GBA1 variant (GBA positive). These individuals will be referred to sister-study, RAPSODI.
  • History of Parkinsonism (progressive supranuclear palsy, multiple system atrophy, traumatic, manganese toxicity, postencephalitic, vascular PD; drug induced PD; corticobasal degeneration)
  • Individuals with another neurological disorder including: dementia, movement disorders, and motor neurone disease.
  • Individuals on drugs known to be associated with parkinsonism, including neuroleptic agents (Amisulpride, Chlorpromazine Hydrochloride, Flupenthixol, Fluphenazine Hydrochloride, Haloperidol, Methotrimeprazine, Levomepromazine, Olanzapine, Oxypertine, Pericyazine, Perphenazine, Pimozide, Pipotiazine, Prochlorperazine, Promazine Hydrochloride, Reserpine, Risperidone, Sulpiride, Thioridazine, Trifluoperazine, Zuclopenthixol acetate, Zotepine), plus Bupropion, , Lithium, Methyldopa, Metoclopramide and Sodium Valproate).
05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
20,000 participants (estimated)
Target follow-up
20 Years
Patient registry
Yes
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. Genotype of participants

    The primary outcome of the study is to genotype the GBA1 gene, obtained with Oxford Nanopore long read sequencing.

    Time frame: 20 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Related links

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2020 (actual). Primary completion is estimated for Jan 2028, 94 months after the start.

Of 381 non-industry observational studies under Parkinson Disease, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 133. This study's planned 94 months is above that.

Counting every sponsor, half of 441 studies reached it within 47 months; a quarter within 22 and three quarters within 114.

Primary completion moved once since we started tracking on Sep 25, 2026: Feb 2025 → Jan 2028, on Oct 29, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 11, 2023
First posted
Nov 30, 2023
StartActual
Feb 15, 2020
Primary completionEst.
Jan 1, 2028was Feb 2025
CompletionEst.
Aug 20, 2040
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Feb 14, 2025→Jan 1, 2028
Oct 29, 2026
Enrollment
4800→20000
Oct 29, 2026
Eligibility
1 exclusion criterion edited
What changed in the criteria
Exclusion criteria
  • EditedConfirmation that the individual carries a GBAGBA1 variant (GBA positive). These individuals will be referred to sister-study, RAPSODI.
Oct 29, 2026
Contact
Study contact changed: p•••@ucl.ac.uk · •••8413→p•••@ucl.ac.uk · •••8413. See the current contact
Oct 29, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • University College London (UCL) · London, United KingdomContact p•••@ucl.ac.uk · •••8413→g•••@ucl.ac.uk · •••8413Contact added p•••@ucl.ac.uk
Oct 29, 2026
Sponsor
University College London Hospitals→University College, London; Collaborators added: Michael J. Fox Foundation for Parkinson's Research
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    Primary completion Feb 14, 2025→Jan 1, 2028
    Enrollment 4800→20000
    Eligibility 1 exclusion criterion edited
    What changed in the criteria
    Exclusion criteria
    • EditedConfirmation that the individual carries a GBAGBA1 variant (GBA positive). These individuals will be referred to sister-study, RAPSODI.
    Sponsor University College London Hospitals→University College, London; Collaborators added: Michael J. Fox Foundation for Parkinson's Research
    Contact Study contact changed: p•••@ucl.ac.uk · •••8413→p•••@ucl.ac.uk · •••8413. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • University College London (UCL) · London, United KingdomContact p•••@ucl.ac.uk · •••8413→g•••@ucl.ac.uk · •••8413Contact added p•••@ucl.ac.uk
    + 7 other changes: index terms, identifiers, verification date, description, conditions, design details and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06151002
Collaborators
Michael J. Fox Foundation for Parkinson's Research, Cure Parkinson's
Responsible party
Anthony Schapira (Professor Anthony Schapira, University College, London) — Principal investigator
First posted
Nov 30, 2023
Start date
Feb 15, 2020
Primary completion
Jan 1, 2028 (estimated)
Completion
Aug 20, 2040 (estimated)
Last update
Oct 29, 2026

Study contacts

PD Frontline Team
Contact
pdfrontline@ucl.ac.uk
020 8016 8413

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion